Welcome to our dedicated page for Avadel Pharmaceu SEC filings (Ticker: AVDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avadel Pharmaceuticals plc filings document the formal record of a completed corporate-status transition, including Nasdaq removal of its ordinary shares on Form 25 and a Form 15 notice covering termination or suspension of Exchange Act reporting obligations after the acquisition by Alkermes plc.
Earlier filings include Form 8-K material-event reports on material agreements, termination of an at-the-market offering agreement, shareholder voting matters, capital-structure disclosure, Regulation FD clinical disclosures for LUMRYZ and REVITALYZ, governance matters, risk factors and operating and financial results.
Avadel Pharmaceuticals plc reports that a U.S. District Court has ordered its subsidiary Avadel CNS Pharmaceuticals to pay Jazz Pharmaceuticals a future ongoing royalty of 3.85% on sales of its sleep medicine LUMRYZ. This royalty will apply through the expiration of Jazz’s U.S. Patent No. 11,147,782 on February 18, 2036.
Avadel disagrees with the underlying jury decision on the patent’s validity and plans to keep contesting both that decision and the related royalty obligation. Despite this, the company states that it has been accruing this royalty and will continue to recognize the related liability on its balance sheet, indicating that the financial impact of the royalty is being reflected in its accounting.
Geoffrey M. Glass, a director of Avadel Pharmaceuticals plc (AVDL), reported a non-cash transfer on Form 4 dated 09/15/2025. He transferred 11,000 stock options with an exercise price of $10.83 and an original grant exercisable from 07/29/2035 to the Geoffrey M. Glass Revocable Trust dated August 26, 2020, of which he is trustee. The options vest in full on the earlier of July 29, 2026 or the next annual shareholders' meeting following grant, subject to continued service. The filing was signed by an attorney-in-fact on Glass’s behalf.
Avadel Pharmaceuticals entered an exclusive global license agreement with XWPharma for valiloxybate, a GABAB receptor agonist for sleep disorders including narcolepsy and idiopathic hypersomnia. The license covers worldwide rights excluding mainland China, Hong Kong and Macau.
Avadel has paid XWPharma an upfront $15 million and will pay an additional $5 million in the fourth quarter of 2025. XWPharma may receive up to $30 million in development milestones, up to $155 million in tiered sales milestones tied to annual net sales up to $750 million, and additional performance-based sales milestone payments equal to 10% of each sales milestone for annual net sales exceeding $750 million and up to $3.5 billion. The agreement also includes tiered royalties from high-single digit to mid-teens on annual net sales and a $10 million milestone after the first U.S. commercial sale for each indication beyond narcolepsy and idiopathic hypersomnia following FDA approval.
The agreement runs until expiration of the applicable royalty terms and includes customary provisions on termination, representations, covenants and indemnification, with Avadel able to terminate for convenience subject to a notice period.
Janus Henderson Group plc reports beneficial ownership stakes in Avadel Pharmaceuticals plc common stock on a Schedule 13G/A filing. The filing names Janus Henderson as the reporting person and lists aggregate holdings of approximately 11.13 million shares (shown as 11,132,131 in one section and 11,080,442 in Item 4), representing about 11.5%–11.4% of the class. The filing identifies indirect subsidiaries JHIUS, JHIUKL and JHIAIFML as involved in investment-advisory activities and states the position is held in the ordinary course of business and not to influence control. The statement is signed by Janus Henderson compliance on 08/14/2025 and references the issuer address in Dublin.
Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi filed a Schedule 13G/A reporting that Two Seas Global (Master) Fund LP holds 6,155,074 ordinary shares of Avadel Pharmaceuticals plc (CUSIP G29687103), representing 6.4% of the class as of June 30, 2025. The filing states that Two Seas Capital LP, as investment adviser to the Global Fund, and Two Seas Capital GP LLC, as its general partner, each may be deemed to have sole voting and dispositive power over these shares, and that Sina Toussi may be deemed to have those powers through his roles with the adviser and GP. The principal business office for the reporting persons is listed as 32 Elm Place, 3rd Floor, Rye, New York 10580. The filing references 96,777,000 shares outstanding used to calculate the 6.4% stake and is signed by Sina Toussi on 08/13/2025. The report covers the event date 06/30/2025.